Phase I and pharmacokinetic study of DACA (XR5000): A novel inhibitor of topoisomerase I and II

British Journal of Cancer

Volumn 80, Issue 11, 1999, Pages 1786-1791

  Twelves, C J ^a   Gardner, C ^b   Flavin, A ^c   Sludden, J ^a   Dennis, I ^c   De Bono, J ^a   Beale, P ^d   Vasey, P ^e   Hutchison, C ^a   Macham, M A ^a   Rodriguez, A ^d   Judson, I ^d   Bleehen, N M ^c  

^a CRC Department of Medical Oncology   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d ROYAL MARSDEN HOSPITAL   (United Kingdom)

^e NONE

Author keywords

Cytotoxic; Pharmacokinetics; Phase I; Topoisomerase I; Topoisomerase II

Indexed keywords

DNA TOPOISOMERASE INHIBITOR; N (2 DIMETHYLAMINOETHYL) 4 ACRIDINECARBOXAMIDE;

ADULT; AGED; ALOPECIA; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW SUPPRESSION; CENTRAL VENOUS CATHETER; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HOT FLUSH; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NAUSEA; NONHUMAN; PAIN; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; STOMATITIS; THORAX PAIN; VOMITING;

ACRIDINES; ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; PAIN; PATIENT SELECTION;

EID: 0032808482     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690598     Document Type: Article

References (18)

1. Abigerges D, Armand J-P, Chabot GG, Bruno R, Bissery M-C, Bayssas M, Klink-Alaki M, Clavel M and Catimel G (1996) Phase I and pharmacology study of intoplicine (RP 60475; NSC 645008), a novel topoisomerase I and II inhibitor, in cancer patients. Anticancer Drugs 7: 166-174
2. Atwell GJ, Rewcastle GW, Baguley BC and Denny WA (1987) Potential anti-tumour agents. 50. In vivo solid tumour activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. J Med Chem 30: 664-669
3. Baguley BC, Holdaway KM and Fray LM (1990) Design of DNA intercalators to overcome topoisomerase II mediated multi-drug resistance. J Natl Cancer Inst 82: 698-402
4. Baguley BC, Zhuang L and Marshall E (1995) Experimental solid tumour activity of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. Cancer Chemother Pharmacol 36: 224-248
5. Evans SMH, Young D, Robertson IGC and Paxton JW (1992) Intraperitoneal administration of the anti-tunour agent of N-[2-(dimethylamino) ethyl] acridine-4-carboxamide in the mouse: bioavailability, pharmacokinetics and toxicity after a single dose. Cancer Chemother Pharmacol 31: 32-36
6. Finlay GJ and Baguley BC (1989) Selectivity of N-[2-(dimethylamino) ethyl] acridine-4-carboxamide towards Lewis lung carcinoma and human tumour cell lines in vitro. Eur J Cancer Clin Oncol 25: 271-277
7. Finlay GJ, Marshall E, Matthews JHL, Paul KD and Baguley BC (1993) In vitro assessment of N-[2-(dimethylamino) ethyl] acridine-4-carboxamide, a DNA intercalating antitumour drug with reduced sensitivity to multidrug resistance. Cancer Chemother Pharmacol 31: 401-406
8. Gupta RS, Gupta R, Eng B, Lock RB, Ross WE, Hertzberg RP, Caranfa MJ and Johns RK (1988) Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I. Cancer Res 48: 6404-6410
9. Kano Y, Suzuki K, Akatsu M, Suda K, Inoue Y, Yoshida M, Sakamoto S and Miura Y (1992) Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 50: 604-610
10. Karato A, Saski Y, Shiraishi J et al (1993) Phase I study of CPT-11 and etoposide in patients with refractory solid tumours. J Clin Oncol 11: 2030-2035
11. Kaufman SH (1991) Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukaemia cell line. Cancer Res 51: 1129-1136
12. Marshall ES, Finlay GJ, Matthews JHL, Shaw JHF, Nixon J and Baguley BC (1992) Microculture-based chemosensitivity testing: a feasibility study comparing treshly explanted human melanoma cells with human melanoma cell lines. J Natl Cancer Inst 84: 340-345
13. Paxton JW, Young D, Evans SMH, Kestell P, Robertson IGC and Comford EM (1992) Pharmacokinetics and toxicity of the anti-tumour agent N-[2-(dimethylamino) ethyl]acridine-4-carboxamide after i.v. administration in the mouse. Cancer Chemother Pharmacol 29: 379-384
14. Paxton JW, Young D, Evans SMH, Robertson IGC and Kestell P (1993a) Tumour profile of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide after intraperitoneal administration in the mouse. Cancer Chemother Pharmacol 32: 320-322
15. Paxton JW, Young D and Robertson IGC (1993b) Pharmacokinetics of acridine-4-carboxamide in the rats, with extrapolation to humans. Cancer Chemother Pharmacol 32: 323-325
16. Schneider E, Darkin SJ, Lawson PA, Ching L.-M. Ralph RK and Baguley BC (1988) Cell line selectivity and DNA breakage properties of the anti tumour agent N-[2-(dimethylamino) ethyl]acridine-4-carboxamide: role of DNA topoisomerase II. Eur J Cancer Clin Oncol 24: 1783-1790
17. Tewey KM, Chen GL, Nelson EM and Liu LF (1984) Intercalative antitumour drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 259: 9182-9187
18. Trast DK and Muller MT (1988) Stabalization of type 1 topoisomerase-DNA covalent complexes by actinomycin D. Porc Natl Acad Sci USA 85: 1417-1421